GlobalData on MSN19h
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseasesApellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
Zacks.com on MSN14h
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority TagThe FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback